Rubicon Research shares had a strong market debut on October 16, with a 28% gain over the issue price. The stock opened at Rs 620 per share on the NSE, representing a premium of 27.84% compared to its IPO price of Rs 485. On the BSE, the shares started trading at Rs 620.10, up 27.86% from the issue price, leading to a market capitalization of approximately Rs 10,216 crore at the time of listing.
Although the debut performance was robust, it fell slightly short of grey market expectations. Before the listing, Rubicon Research shares were trading at a nearly 30% premium in the unlisted market. The company’s initial public offering (IPO) of Rs 1,377.50 crore garnered significant interest from investors, with the subscription being 48 times oversubscribed. Non-institutional investors (NIIs) played a key role, subscribing over 80 times their allocated portion, indicating a growing interest in the pharmaceutical and healthcare research sector, where Rubicon Research operates.
The IPO comprised a fresh issue of shares worth Rs 500 crore and an offer for sale (OFS) of shares worth Rs 877.5 crore by its promoter, General Atlantic Singapore RR. The pricing range for the IPO was set between Rs 461 and Rs 485 per share. Proceeds from the fresh issue, amounting to Rs 310 crore, are planned to be used for debt repayment to enhance the company’s financial position. The remaining funds will be allocated towards potential acquisitions and general corporate purposes.
Despite earlier expectations of a higher grey market premium, the final listing price of Rs 620 per share resulted in a slightly lower premium. Analysts noted that the strong demand and positive listing signify confidence in Rubicon Research’s long-term growth prospects, despite the marginal variation. Specializing in innovative drug delivery solutions, Rubicon Research is a pharmaceutical product development company catering to global clients, particularly in regulated markets like the United States and Europe, with a growing presence in emerging markets. Its product portfolio includes various formulations such as oral solids, ophthalmic solutions, topical products, and complex injectables, allowing for steady expansion through global partnerships and a diverse product pipeline.